Shopping Cart
Remove All
Your shopping cart is currently empty
N-Desethyl Sunitinib (SU012662) is the primary active metabolite of Sunitinib produced by the metabolism of cytochrome P450 enzyme 3A4 (CYP3A4).Sunitinib is an orally available inhibitor of a number of tyrosine kinases involved in tumor proliferation and angiogenesis, including VEGFR, PDGFR, KIT, and FLT3, and was approved for the treatment of advanced/metastatic renal cell carcinoma (RCC)

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 2 mg | $77 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $152 | 7-10 days | 7-10 days |
| Description | N-Desethyl Sunitinib (SU012662) is the primary active metabolite of Sunitinib produced by the metabolism of cytochrome P450 enzyme 3A4 (CYP3A4).Sunitinib is an orally available inhibitor of a number of tyrosine kinases involved in tumor proliferation and angiogenesis, including VEGFR, PDGFR, KIT, and FLT3, and was approved for the treatment of advanced/metastatic renal cell carcinoma (RCC) |
| Synonyms | SU-11662, SU11662 |
| Molecular Weight | 370.42 |
| Formula | C20H23FN4O2 |
| Cas No. | 356068-97-8 |
| Smiles | C(=C\1/C=2C(NC1=O)=CC=C(F)C2)\C3=C(C)C(C(NCCNCC)=O)=C(C)N3 |
| Relative Density. | 1.265 g/cm3 (Predicted) |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||
| Solubility Information | DMSO: 4 mg/mL (10.8 mM), Sonication is recommended. | ||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||
DMSO
| |||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.